Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zymeworks Inc (NQ: ZYME )

11.56 -0.20 (-1.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 839,988
Open 11.78
Bid (Size) 11.02 (1)
Ask (Size) 12.04 (1)
Prev. Close 11.76
Today's Range 11.35 - 11.95
52wk Range 6.015 - 13.14
Shares Outstanding 57,771,204
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire

Performance

YTD
+11.37%
+11.37%
1 Month
+13.33%
+13.33%
3 Month
+28.87%
+28.87%
6 Month
+4.62%
+4.62%
1 Year
+62.36%
+62.36%

More News

Read More
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
From Zymeworks Inc.
Via GlobeNewswire
Navigating 6 Analyst Ratings For Zymeworks
Via Benzinga
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
From Zymeworks Inc.
Via GlobeNewswire
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
Via Talk Markets
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
From Zymeworks Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.